Continuing Education
for Urology & GU Oncology Clinicians

Conference Coverage: SUO 2019 Prostate

Washington, DC (UroToday.com) An award was created in honor of the late Dr. Richard D. William, and this year’s recipient is long-time contributor and leader in the field Dr. William Catalona who presented his experience with PSA screening over the years.

Non-Accredited

Washington, DC (UroToday.com) While PSA screening has resulted in decreasing prostate cancer mortality, PSA is also known to be a poorly specific test for the detection of clinically significant cancer and can lead to unnecessary biopsies, over-detection of low risk prostate cancer or even miss aggressive disease. PSA’s lack of robustness as a screening biomarker has led to the development of new prostate cancer screening tools (urine, blood, and imaging-based) to add specificity to PSA for the detection of clinically significant prostate cancer. During the oral abstract session at the 20th Annual Meeting of the Society of Urologic Oncology, Dr. Claire De La Calle and colleagues presented results of their study evaluating and comparing three screening tools in the clinical setting: serum based 4K score and urine based studies SelectMDX and ExoDx™. Their objective was to assess these three study’s added value for the detection of clinically significant prostate cancer when combined with multiparametric parametric MRI (mpMRI).

Non-Accredited

Washington, DC (UroToday.com) To conclude the Society of Urologic Oncology (SUO) 2019 advanced prostate cancer session, Dr. Joaquin Mateo provided an overview of PARP inhibitors in prostate cancer. Metastatic prostate cancer remains a lethal disease, however, abiraterone, enzalutamide, and radium-223 have prolonged survival. Currently, the one-size-fits-all approach remains the standard of care in metastatic castration-resistant prostate cancer (mCRPC). As we learn more about mCRPC, Dr. Mateo notes that we identify potential additional targets for tailored treatment.

Non-Accredited